DSM-Firmenich Future Growth

Future criteria checks 3/6

DSM-Firmenich is forecast to grow earnings and revenue by 49.2% and 6.8% per annum respectively. EPS is expected to grow by 51.1% per annum. Return on equity is forecast to be 5.3% in 3 years.

Key information

49.2%

Earnings growth rate

51.1%

EPS growth rate

Chemicals earnings growth	21.7%
Revenue growth rate	6.8%
Future return on equity	5.3%
Analyst coverage	Good
Last updated	06 May 2024

Recent future growth updates

Recent updates

Here's Why DSM-Firmenich (AMS:DSFIR) Can Afford Some Debt

Apr 27

DSM-Firmenich AG (AMS:DSFIR) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 18

Earnings and Revenue Growth Forecasts

ENXTAM:DSFIR - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	13,723	934	1,057	1,952	16
12/31/2025	13,300	781	955	1,938	20
12/31/2024	12,630	452	973	1,891	19
12/31/2023	10,627	-658	573	1,265	N/A
9/30/2023	9,686	-456	434	1,112	N/A
6/30/2023	8,745	-254	287	959	N/A
3/31/2023	8,568	100	301	962	N/A
12/31/2022	8,390	454	314	965	N/A
9/30/2022	9,582	837	412	1,056	N/A
6/30/2022	7,867	823	510	1,147	N/A
3/31/2022	7,568	822	680	1,287	N/A
12/31/2021	7,269	820	850	1,427	N/A
9/30/2021	7,955	660	884	1,507	N/A
6/30/2021	7,558	493	906	1,489	N/A
3/31/2021	7,572	423	906	1,497	N/A
12/31/2020	8,106	448	868	1,494	N/A
9/30/2020	7,960	510	809	1,434	N/A
6/30/2020	8,034	557	810	1,462	N/A
3/31/2020	9,011	722	826	1,471	N/A
12/31/2019	7,998	675	744	1,385	N/A
9/30/2019	8,272	820	766	1,399	N/A
6/30/2019	8,502	794	747	1,395	N/A
3/31/2019	9,124	934	612	1,282	N/A
12/31/2018	9,267	1,069	698	1,391	N/A
9/30/2018	9,235	984	657	1,310	N/A
6/30/2018	9,106	2,082	550	1,170	N/A
3/31/2018	8,908	1,942	512	1,110	N/A
12/31/2017	8,632	1,761	441	996	N/A
9/30/2017	8,471	1,676	N/A	993	N/A
6/30/2017	8,333	738	N/A	1,028	N/A
3/31/2017	8,166	711	N/A	1,077	N/A
12/31/2016	7,920	645	N/A	1,018	N/A
9/30/2016	7,831	588	N/A	958	N/A
6/30/2016	7,778	274	N/A	914	N/A
3/31/2016	7,749	214	N/A	811	N/A
12/31/2015	7,722	174	N/A	696	N/A
9/30/2015	7,607	66	N/A	800	N/A
6/30/2015	7,456	114	N/A	820	N/A
3/31/2015	7,245	115	N/A	867	N/A
12/31/2014	7,051	123	N/A	808	N/A
9/30/2014	7,415	112	N/A	866	N/A
6/30/2014	7,834	138	N/A	885	N/A
3/31/2014	8,362	182	N/A	1,010	N/A
12/31/2013	8,858	252	N/A	998	N/A
9/30/2013	8,409	363	N/A	705	N/A
6/30/2013	8,500	335	N/A	638	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DSFIR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).

Earnings vs Market: DSFIR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DSFIR is expected to become profitable in the next 3 years.

Revenue vs Market: DSFIR's revenue (6.8% per year) is forecast to grow slower than the Dutch market (9.2% per year).

High Growth Revenue: DSFIR's revenue (6.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DSFIR's Return on Equity is forecast to be low in 3 years time (5.3%).

DSM-Firmenich Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 37%

Consensus EPS estimates increase by 24%, revenue downgraded

Consensus EPS estimates increase by 73%, revenue downgraded

Consensus EPS estimates fall by 19%

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 13%

Recent updates

Dsm-Firmenich Ag Approves Retirement of Pradeep Pant from the Board

Here's Why DSM-Firmenich (AMS:DSFIR) Can Afford Some Debt

Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR).

DSM-Firmenich AG (AMS:DSFIR) Shares Could Be 31% Below Their Intrinsic Value Estimate

Full year 2023 earnings: EPS and revenues exceed analyst expectations

DSM-Firmenich AG Proposes Dividend for the Financial Year 2023

DSM-Firmenich AG Proposes Dividend for the Financial Year 2023

DSM-Firmenich AG to Report First Half, 2024 Results on Jul 30, 2024

DSM-Firmenich Makes Voluntary Cash Offer for DSM Shares

DSM-Firmenich AG's (AMS:DSFIR) Share Price Could Signal Some Risk

Now 20% undervalued

Are Investors Undervaluing DSM-Firmenich AG (AMS:DSFIR) By 23%?

DSM-Firmenich AG, Annual General Meeting, May 07, 2024

dsm-firmenich Achieves Regulatory Clearance in China for Two HMO Ingredients for Early Life Nutrition

Getting In Cheap On DSM-Firmenich AG (AMS:DSFIR) Is Unlikely